{
    "nct_id": "NCT06028022",
    "official_title": "Reishi Mushroom Extract for Fatigue and/or Arthralgias in Patients With Breast Cancer on Aromatase Inhibitors: A Randomized Phase II MNCCTN Trial",
    "inclusion_criteria": "* Age ≥ 18 years\n* History of breast cancer, estrogen receptor positive (ER+), Her 2 positive or negative\n* Fatigue ≥ 4/10\n* Currently post-menopausal (as defined by National Comprehensive Cancer Network (version 4.2024), taking any aromatase inhibitor in the curative setting and planning to be on such for at least 8 weeks after registration. [Patients on concurrent ovarian suppression (such as with leuprolide acetate, goserelin) are allowed]; CDK 4/6 inhibitors abemaciclib, ribociclib ARE allowed\n* Prior treatment: last chemotherapy ≥ 90 days prior to randomization (if treated with chemotherapy)\n* On a stable dose of pain medications if pain medications are being regularly used. (i.e., no change in dosage in the past 30 days)\n* If on supplements, must be on stable dose with no plan to change; not on or planning any acupuncture or other specific supportive modalities for fatigue or AI arthralgias\n* Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0, 1 or 2\n* White blood cell count (WBC) ≥ 3,000/mm^3 (obtained ≤ 30 days prior to randomization)\n* Hemoglobin ≥ 10 g/dL (obtained ≤ 30 days prior to randomization)\n* Platelet count ≥ 100,000/mm^3 (obtained ≤ 30 days prior to randomization)\n* Total bilirubin ≤ 1.5 x upper limit of normal (ULN) (obtained ≤ 30 days prior to randomization)\n* Alanine aminotransferase (ALT) or aspartate transaminase (AST) ≤ 1.2 x ULN (obtained ≤ 30 days prior to randomization)\n* Prothrombin time (PT)/activated partial thromboplastin time (aPTT) ≤ 1.5 x ULN (obtained ≤ 30 days prior to randomization)\n* Negative pregnancy test done ≤ 7 days prior to registration, for persons on concurrent ovarian suppression only\n* Provide informed consent\n* Ability to complete questionnaires\n* Willing to return to enrolling institution during the active monitoring phase of the study\nHealthy volunteers allowed\nMust be FEMALE\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Other known uncontrolled medical conditions causing fatigue such as untreated thyroid disease, depression, fibromyalgia, chronic fatigue syndrome, infection, autoimmune disease, or active/untreated hepatitis\n* Allergy to mushrooms\n* On anticoagulation medication or aspirin or having a known bleeding disorder\n* On any specific medication for fatigue (e.g., methylphenidate)\n* Metastatic cancer diagnosis (history of nodal metastases is allowed)\n* Chronic steroid use, unless on physiologic replacement doses\n* Current use of any medical mushrooms\n* On medications for diabetes\n* History of symptomatic hypotension\n* Taking CYP3A4, CYP2D6 sensitive substrates which can be located at the following link:\n\nhttps://www.fda.gov/drugs/drug-interactions-labeling/healthcare-professionals-fdas-examples-drugs-interact-cyp-enzymes-and-transporter-systems\n\n* Drugs which exhibit either >20% inhibition or >20% induction of CYP2E1 in vivo, such as: Acetaminophen, Dapsone, Enflurane, Halothane, Isoflurane, & Theophylline\n* Taking olaparib\n* Any of the following because this study involves an agent that has unknown genotoxic, mutagenic and teratogenic effects:\n\n  * Pregnant persons\n  * Nursing persons\n  * Persons on concurrent ovarian suppression who are unwilling to employ adequate contraception (e.g., hormonal methods, barrier methods, intrauterine device, abstinence)",
    "miscellaneous_criteria": ""
}